Cannabis Medical Program Qualifying Conditions in South Africa

There is no official qualifying conditions list

South Africa does not operate a US-style medical cannabis program. There is no statutory list of qualifying conditions, no state-issued patient card, and no public patient registry Strong evidence. SAHPRA, the national medicines regulator, controls access to cannabis-containing medicines under the Medicines and Related Substances Act 101 of 1965 ^[1][2].

This is the single most misunderstood point in South African cannabis policy. Clinics and dispensaries that advertise 'qualifying conditions' are typically reproducing internal clinical criteria or copying lists from other jurisdictions (Israel, Germany, US states). Those lists have no force of law in South Africa Strong evidence.

How legal medical access actually works

There are two legal routes to cannabis-based medicine in South Africa:

1. Registered/scheduled CBD products. In 2019 the Minister of Health issued an exclusion notice and amended schedules so that low-dose cannabidiol preparations (broadly: ≤20 mg/day CBD, with low THC, in pack sizes ≤600 mg) became available as Schedule 0 or Schedule 4, depending on the claim and concentration ^[3][4]. The original 12-month exclusion notice has been extended/renewed; check the current Government Gazette for the version in force.

2. Section 21 of Act 101 of 1965. For anything stronger — THC-containing oils, dried flower for medical use, or specific CBD doses outside the schedule — a registered medical practitioner must apply to SAHPRA for authorisation to prescribe an unregistered medicine for a named patient ^[1][5]. SAHPRA evaluates each application on the clinical merits submitted by the doctor.

There is no third 'medical card' route. Anyone offering a 'medical cannabis licence' or 'patient card' outside these two mechanisms is operating outside the regulatory framework Strong evidence.

Conditions doctors commonly motivate for

Because the decision is clinician-led, the practical 'list' is whatever conditions South African prescribers can build an evidence-based motivation for. SAHPRA's own Section 21 guidance and published literature most commonly support applications for:

• Chronic pain unresponsive to first-line therapy Strong evidence
• Chemotherapy-induced nausea and vomiting Strong evidence
• Spasticity in multiple sclerosis Strong evidence
• Treatment-resistant paediatric epilepsies, particularly Dravet and Lennox-Gastaut syndromes (where CBD has the strongest evidence) Strong evidence
• Palliative care symptom control Weak / limited
• Anxiety, PTSD, and insomnia Weak / limited

These reflect the evidence base reviewed by bodies like the US National Academies and Cochrane, not a South African statutory list ^[6][7]. A prescriber may motivate for other indications, but the strength of the application turns on the published evidence for that specific condition. Claims that cannabis 'treats' cancer, autism, or HIV in any curative sense are not supported by controlled clinical evidence No data.

What a Section 21 application requires

The doctor — not the patient — submits the application. SAHPRA's Section 21 application typically requires ^[5]:

• Patient details and diagnosis (ICD-10 coded)
• Clinical motivation including previous treatments tried and failed
• The specific product, dose, and treatment duration requested
• Source/supplier details for the unregistered product
• Informed consent from the patient
• Practitioner declaration of monitoring and adverse event reporting

Authorisations are product-specific and time-limited. They do not confer any right to grow cannabis, possess flower outside the dispensed product, or share medicine with others Strong evidence.

Private adult use is a separate question

In Minister of Justice and Constitutional Development v Prince (2018), the Constitutional Court decriminalised the private use, possession, and cultivation of cannabis by adults in private ^[8]. The Cannabis for Private Purposes Act was signed into law in May 2024, codifying private adult use but explicitly not creating a commercial recreational market and not changing the medical framework ^[9]. Medical cannabis access still runs through SAHPRA. Personal private cultivation under the Prince judgment is a separate legal track and is not a substitute for a Section 21 prescription if you want pharmaceutical-grade product or legal supply through a clinic Strong evidence.

Recent changes and what to watch

• May 2024: Cannabis for Private Purposes Act signed into law (commencement date pending proclamation as of last verification) ^[9].
• 2023–2024: SAHPRA continued to refine its cannabis licensing framework for cultivators and manufacturers; this is a supply-side change, not a patient-access change.
• CBD exclusion notice: has been renewed since 2019; check the current Government Gazette before assuming a product is Schedule 0 ^[3][4].

Information last verified: 15 June 2024. Regulatory status changes; always confirm against the current Government Gazette and SAHPRA website before acting.

This is not legal advice

This article is informational and reflects the regulatory framework as best understood at the verification date above. It is not legal advice and not medical advice. If you are seeking medical cannabis in South Africa, speak to a registered medical practitioner who has experience submitting Section 21 applications. If you have a legal matter — possession charges, cultivation disputes, or licensing questions — consult a South African attorney.

Sources

How this page was made